ARTICLE | Clinical News

Namzaric memantine ER/donepezil regulatory update

January 5, 2015 8:00 AM UTC

FDA approved an NDA from Actavis’ Forest Laboratories Inc. subsidiary for Namzaric memantine extended-release/donepezil to treat moderate to severe dementia of the Alzheimer’s type in patients stabilized on memantine and donepezil. Actavis expects to launch Namzaric next quarter. The product is a once-daily, fixed-dose combination of memantine ER, an NMDA receptor antagonist, and donepezil, an acetylcholinesterase (AChE) inhibitor. Forest markets Namenda XR memantine and Aricept donepezil. ...